ABVC BioPharma Provides 2023 Pipeline Update
FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Year: 2023
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Research illustrates company’s progress in working to end the diagnostic odyssey and includes data with implications for how care is...
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over...
Assure Holdings to Present at the Gravitas 6th Annual Growth Conference
DENVER, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement
YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth...
Struggling With Intimacy? Male Plus Can Help.
The Belgian Brand’s Trio of 100% Natural Ingredients Restores the Fun in the BedroomFORT LAUDERDALE, FL, Feb. 27, 2023 (GLOBE...
Male Plus Can Boost the Libido for Days at a Time
A Single Dose Can Spark Sexual Interest for Multiple Days at a TimeFort Lauderdale, FL, Feb. 27, 2023 (GLOBE NEWSWIRE)...
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or...
Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic...
Sirona Biochem Receives Antiviral Testing Results
VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is...
Exagen Inc. to Participate in Upcoming March Conferences
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that...
Anthropologist Wade Davis to Join Dimensions Algonquin Highlands for the opening of ASCEND + Retreat
TORONTO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Dimensions, a Canadian company offering retreat experiences for personal growth, well-being, and creative...
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...
Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board
Increases Key Opinion Leaders to 13 Throughout the Americas, Israel, and Europe to Support the Company’s Next Regulatory and Commercialization...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare...